Valuation: Emergent BioSolutions Inc.

Market Cap 420M 368M 340M 314M 596M 40.22B 608M 4.09B 1.59B 19.68B 1.58B 1.54B 68.32B P/E 2026 *
-26.7x
P/E 2027 * 8.95x
Enterprise Value 420M 368M 340M 314M 596M 40.22B 608M 4.09B 1.59B 19.68B 1.58B 1.54B 68.32B EV / Sales 2026 *
0.57x
EV / Sales 2027 * 0.47x
Free-Float
81.07%
Yield 2026 *
-
Yield 2027 * -
06-29 Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000 CI
06-29 Emergent Gets $52.7 Million Contract Modification From US Government MT
06-08 Emergent BioSolutions Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02:00 PM
05-28 Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT MT
05-28 Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy RE
05-28 Emergent BioSolutions Inc. Receives USD 64.5 Million Contract Modification from the Administration for Strategic Preparedness and Response for Supply of BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) ?] CI
05-18 Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for Smallpox, Mpox Vaccine MT
05-18 Emergent BioSolutions Receives Saudi Food And Drug Authority Approval For ACAM2000 CI
05-01 Emergent BioSolutions Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30 Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. CI
04-30 Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on February 26, 2026. CI
04-30 Emergent BioSolutions Inc. Provides Earnings Guidance for the Second Quarter and Updates Earnings Guidance for Full Year 2026 CI
04-30 Emergent BioSolutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-1.81%
1 week-1.69%
Current month-2.86%
1 month+1.75%
3 months-2.98%
6 months-39.07%
Current year-34.14%
1 week 8.04
Extreme 8.04
8.43
1 month 7.58
Extreme 7.58
8.63
Current year 7.53
Extreme 7.5318
14.06
1 year 5.62
Extreme 5.615
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
68.03
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 2024-02-20
Director of Finance/CFO 62 2018-03-25
Chief Tech/Sci/R&D Officer 53 2024-11-17
Director TitleAgeSince
Chairman 82 2022-03-31
Director/Board Member 70 2004-12-31
Director/Board Member 77 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Executive/Senior Manager

-3,000 0.0058%
06-07Tax

Compliance Officer

-2,018 0.0039%
06-07Tax

Executive/Senior Manager

-694 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%-1.69%+18.49%+15.62% 420M
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-0.43%-2.28%+28.35%+25.81% 330B
-9.63%-11.05%+24.80%+27.03% 295B
-0.65%-2.11%+28.47%+46.09% 285B
-0.97%-3.55%-27.73%-39.69% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average -1.45%+2.10%+27.72%+54.65% 366.03B
Weighted average by Cap. -0.90%+2.48%+40.15%+85.16%

Financials

2026 *2027 *
Net sales 733M 643M 594M 549M 1.04B 70.19B 1.06B 7.14B 2.77B 34.35B 2.75B 2.69B 119B 892M 782M 722M 667M 1.27B 85.41B 1.29B 8.68B 3.37B 41.8B 3.35B 3.28B 145B
Net income -15.98M -14.02M -12.94M -11.96M -22.67M -1.53B -23.12M -156M -60.45M -749M -60.02M -58.71M -2.6B 47.92M 42.03M 38.8M 35.86M 67.97M 4.59B 69.33M 466M 181M 2.25B 180M 176M 7.79B
Net Debt - -
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
26-07-08 US$8.140 -1.81% 847,809
26-07-07 US$8.290 +1.34% 675,388
26-07-06 US$8.180 -1.21% 610,900
26-07-02 US$8.280 0.00% 575,960
26-07-01 US$8.280 -1.19% 555,463
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.140USD
Average target price
12.00USD
Spread / Average Target
+47.42%

Quarterly revenue - Rate of surprise